ProQR Therapeutics NV (PRQR) Trading Up 8.2%
ProQR Therapeutics NV (NASDAQ:PRQR)’s share price was up 8.2% during mid-day trading on Tuesday . The stock traded as high as $6.80 and last traded at $6.60, with a volume of 143,377 shares changing hands. The stock had previously closed at $6.10.
Several equities analysts recently issued reports on PRQR shares. Chardan Capital started coverage on shares of ProQR Therapeutics NV in a report on Monday, June 20th. They issued a “neutral” rating and a $4.50 target price on the stock. Leerink Swann restated a “buy” rating on shares of ProQR Therapeutics NV in a report on Thursday, August 18th. Zacks Investment Research lowered shares of ProQR Therapeutics NV from a “hold” rating to a “sell” rating in a report on Saturday, August 20th. Finally, JMP Securities reaffirmed a “buy” rating on shares of ProQR Therapeutics NV in a research note on Tuesday, September 6th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $15.94.
The company’s market capitalization is $154.55 million. The firm’s 50 day moving average is $5.49 and its 200-day moving average is $5.07.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/proqr-therapeutics-nv-prqr-trading-up-8-2.html
ProQR Therapeutics NV (NASDAQ:PRQR) last released its earnings results on Wednesday, August 17th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.00. On average, analysts predict that ProQR Therapeutics NV will post ($2.14) EPS for the current year.
A hedge fund recently raised its stake in ProQR Therapeutics NV stock. Sabby Management LLC boosted its stake in shares of ProQR Therapeutics NV (NASDAQ:PRQR) by 276.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 149,934 shares of the biopharmaceutical company’s stock after buying an additional 110,063 shares during the period. Sabby Management LLC owned approximately 0.64% of ProQR Therapeutics NV worth $732,000 as of its most recent filing with the SEC. Institutional investors own 39.21% of the company’s stock.
ProQR Therapeutics NV Company Profile
ProQR Therapeutics N.V. (ProQR), formerly ProQR Therapeutics B.V., is a pre-clinical stage biopharmaceutical company. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Utilizing its RNA repair technologies, the Company is developing a pipeline in severe genetic disorders, such as cystic fibrosis (CF) and Leber’s congenital amaurosis (LCA).
Receive News & Ratings for ProQR Therapeutics NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics NV and related companies with MarketBeat.com's FREE daily email newsletter.